Compare Bristol-Myers Squibb Co (BMY) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Marathon Digital Holdings Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Marathon Digital Holdings Inc trades at $9.64 (market cap $3.74B). The key difference: Bristol-Myers Squibb Co is far larger — about 34.7× Marathon Digital Holdings Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals.
| BMY | MARA | |
|---|---|---|
Market Cap | $129.94B | $3.74B |
Sector | Health | Technology |
52-Week High | $65.89 | $22.84 |
52-Week Low | $42.60 | $6.73 |
Enterprise Value | $163.92B | $5.78B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
MARA Holdings trades at $9.675, down 1.2% on the day, with a bearish technical signal and negative earnings trends. The company reported a Q2 2026 net loss of $1.60 per share, missing estimates, while revenue declined to $804 million in 2026. Despite a 50% analyst buy rating and a $16.08 consensus price target, profitability remains challenged with a -429.71% net income margin. Recent news highlights a strategic pivot toward AI digital infrastructure amid Bitcoin mining headwinds.
The outlook is mixed: valuation ratios like P/E of 3.37 suggest potential undervaluation, but persistent losses and high debt-to-asset ratio of 49.43% pose significant risks. Upside depends on successful execution of the AI infrastructure strategy, while downside risks include continued earnings misses and cryptocurrency market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
